Saturday, January 31, 2026

WHEN WILL US LEARN? Washington Shifts To ‘Coexistence’ While China Threatens Taiwan With War

The U.S. is shifting from viewing China as an adversary to a manageable partner, aiming for economic coexistence despite tensions.

North Korea Promotes Kim Jong-un As “Father” From New Year… “Family Narrative” Highlighted For Internal Unity

North Korea emphasizes Kim Jong Un's familial image as a benevolent leader, promoting unity and the socio-political organism theory.

Tumors Shrinking, Hopes Rising: Voronoi’s VRN11 Shows Over 40% Tumor Reduction in Early Lung Cancer Trial

Voronoi's VRN11 shows promising anti-cancer efficacy in early trials, reducing tumors in resistant lung cancer patients without major side effects.

Tag: pharmaceutical

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

Eli Lilly vs. Novo Nordisk: A $1.2 Billion Bet Reveals Two Very Different Futures for Obesity Drugs

Eli Lilly and Novo Nordisk are pursuing different strategies in the obesity treatment market, focusing on expansion versus core strengths.

2025’s Drug Price Revolution: What Asian Pharma Firms Need to Know About MFN Policies

Trump's second term sees U.S. drug pricing reforms and supply chain shifts, prompting South Korean firms to seize new opportunities.

JW Pharmaceutical Secures U.S. Patent for Hair Loss Drug Candidate JW0061

JW Pharmaceutical secures a U.S. patent for hair loss treatment JW0061, targeting GFRA1 receptor, ensuring market exclusivity until 2039.

Unlocking Convenience: Rolvedon’s Same-Day Chemotherapy Solution for Neutropenia Revealed

Hanmi Pharmaceutical's Rolvedon shows potential for same-day chemotherapy administration, improving patient convenience and market competitiveness.

Chinese & Indian Medical Invasion: Pharmaceutic Dependency on Risk of Essential Medicine Supply

Concerns rise over South Korea's API industry reliance on China and India, with self-sufficiency at a record low of 25.6% in 2023.

From R&D to Global Blockbuster: Fexuclue Sparks a New Vision for Daewoong

Daewoong Pharmaceutical's Fexuclue achieves rapid success with innovative marketing and aims for significant growth in treating GERD.

New Obesity Pill Could End Wegovy’s Reign, Offering Faster and Safer Results

Ildong's ID110521156 shows promise as an affordable GLP-1 obesity drug with fewer side effects, aiming to transform the treatment landscape.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.